Why Natural Gas Jumped as Gold and Silver Fell on November 20, 2026
Natural gas rose 16% while silver and gold futures fell on November 20, 2026. See the verified market data, possible drivers, key caveats and next-session scenarios.
Verified and updated: November 21, 2026, 8:30 a.m. AEDT (Sydney; UTC+11).
Australia’s Therapeutic Goods Administration (TGA) has registered Foundayo (orforglipron), a daily oral GLP-1 medicine for weight management and type 2 diabetes in eligible adults. The TGA published its decision summary on November 20, following registration on November 16. The approval adds a new pill option to a fast-changing treatment landscape that already includes injectable medicines and, as of this month, tablet-form Wegovy.
Searches for “Ayo weight loss pill Australia” may be referring to Foundayo. The TGA’s registered product is named Foundayo; “Ayo” is not the name used in the regulator’s decision. Registration means the product has been entered in Australia’s Register of Therapeutic Goods, but it does not by itself confirm pharmacy availability, launch timing, price or PBS subsidy. Those details should be checked with a prescriber and pharmacist as they become available.
The TGA’s decision summary identifies Foundayo’s active ingredient as orforglipron and says it is approved, with a healthy diet and regular physical activity, for weight management and type 2 diabetes in eligible adults. The regulator lists tablets and capsules. The medicine belongs to the GLP-1 receptor agonist class, but it is a new oral option rather than a rebrand of semaglutide or tirzepatide.
In its evidence summary, the TGA describes two 72-week weight-management trials. In ATTAIN-1, adults without type 2 diabetes taking the highest studied dose lost 9.1% more body weight than the placebo group. In ATTAIN-2, involving adults with type 2 diabetes, average weight changes ranged by dose: the highest dose group lost 9.61% of starting weight, compared with 2.46% for placebo. These are trial results, not a promise of an individual outcome. Participants’ responses varied, and treatment was studied alongside diet and activity.
The TGA lists nausea, constipation, diarrhoea, vomiting and indigestion among commonly reported side effects, mostly mild to moderate in the clinical studies. It advises patients to consult the medicine’s Consumer Medicine Information and Product Information for full risk and use details. A clinician can assess whether a particular medicine is appropriate, taking account of medical history, other medicines and treatment goals.
Foundayo’s news value is the arrival of another oral route into a market where many established GLP-1 treatments are injections. The TGA also registered Wegovy tablets in November 2026. Wegovy contains semaglutide; Foundayo contains orforglipron. They are distinct medicines, with separate prescribing information and dosing. Injectable semaglutide (Wegovy) and tirzepatide (Mounjaro) are other registered weight-management options for eligible patients. Ozempic is a semaglutide brand approved for type 2 diabetes and should not be treated as interchangeable with a weight-management prescription.
Australian Government PBS material available for this review says GLP-1 medicines are not subsidised through the PBS for the purpose of weight loss. The PBAC has recommended Wegovy for a narrower group—people with established cardiovascular disease and obesity—subject to a price reduction and risk-sharing arrangement. A recommendation is not the same as a PBS listing: patients should check the current PBS schedule and ask their clinician or pharmacist about the applicable indication, eligibility and out-of-pocket cost. No Australian price or confirmed retail launch date for Foundayo was established in the TGA decision summary reviewed here.
Start with a GP or another qualified prescriber, who can review health history, weight-related conditions, current medicines and appropriate treatment choices. Ask whether the medicine is approved for the intended use, when it can actually be obtained, what it may cost and what monitoring or follow-up is needed. Do not buy prescription medicines from unfamiliar websites or rely on a social-media post to identify an approved product.
The TGA has warned about unregistered products advertised online as “GLP-1” drops, liquids or peptides. Such products may be falsely labelled, contain undisclosed ingredients or lack evidence of effectiveness. The regulator says GLP-1 medicines are prescription-only and advises consumers to obtain them through legitimate medical care and registered pharmacies. Separately, Australian rules restrict compounding of GLP-1 analogue products by pharmacists from October 1, 2024, subject to the regulatory framework and any applicable exceptions.
For readers searching “Ayo,” verify the exact name on any advertisement or product. The current TGA announcement concerns Foundayo. If a seller uses a different name or claims that an unregistered supplement is a GLP-1 medicine, check the ARTG and talk to a health professional before taking it.
The immediate practical questions are commercial supply, pharmacy availability, prescribing guidance and whether any future subsidy decision changes patient costs. These are separate from TGA registration and may be updated after this article’s check. Oral dosing could suit some patients who prefer tablets, but a pill is not automatically safer, cheaper or more suitable than an injection. Comparative choices depend on the approved indication, evidence, side-effect profile, access and individual clinical circumstances.
For current primary information, consult the TGA Foundayo decision summary, the TGA Wegovy decision summary, the PBS consumer summary on GLP-1 access, and the TGA’s alert about imported unregistered GLP-1 products. Information checked November 21, 2026; supply, pricing and subsidy status can change.
The TGA decision reviewed is for Foundayo (orforglipron). “Ayo” is not the product name in that decision; confirm any product claim with the TGA or a pharmacist.
The TGA registered it on November 16, 2026, but its decision summary does not confirm retail launch timing, pharmacy stock or price. Ask a prescriber or pharmacist for current supply information.
PBS material reviewed for this article says GLP-1 medicines are not subsidised for weight loss. Check the current PBS schedule because subsidy decisions and eligible indications may change.
Natural gas rose 16% while silver and gold futures fell on November 20, 2026. See the verified market data, possible drivers, key caveats and next-session scenarios.
Broadcom, Tesla and Meta fell sharply on November 20 as an AI-linked sell-off deepened. Here are the verified market drivers and conditional scenarios for Monday’s session.
Nvidia fell 14.0% to $125.53 on November 20 as a broad AI-stock selloff deepened and a Reuters report on SEC accounting scrutiny added pressure. Here are the verified factors and next-session scenarios.
U.S. stocks fell sharply on November 20 as AI-linked shares sold off. See reported index closes, why volatility surged, and what could shape the next session.
Coal River Farm is trading in the immediate term during voluntary administration. Here’s what customers should check about orders, bookings, and gift cards.
Bitcoin fell below $60,000 on Nov. 20 as a technology-stock selloff and ETF outflows weighed on risk appetite. See the latest verified BTC market context.
Coal River Farm is trading in the short term under administrator Adam Johnston, who is seeking urgent proposals for the Tasmanian cheese and chocolate business.
Australia’s TGA registered oral Wegovy and Foundayo in November. See what approval means for access, likely costs, safety and practical next steps.
Learn how GLP-1 medicines affect appetite, what the latest Australian approvals mean, and the safety questions to discuss with your clinician.
Australia’s TGA has registered Foundayo (orforglipron), a daily GLP-1 tablet for eligible adults. See what is approved, what remains unclear and how it compares with current options.